Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW679769 dose-finding for prevention of nausea and vomiting with moderately emetogenic chemotherapy
2004-001020-20Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vercirnon in chemotherapy-induced nausea and vomiting (CINV), sponsored by GSK. Started Dec 2004; status: completed.
02
Drugs
vercirnon
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2004-001020-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001020-20.